옵션 체인은 다양한 행사가격과 만기일에 대한 Novo Nordisk의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Novo Nordisk에 대한 시장 심리를 평가합니다..

Novo Nordisk (NYSE:NVO) 주식, 옵션 체인

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Long Ideas

News

Short Ideas

Trading Ideas

$BTC

$DOGE

AAPL

ENVX

EVGO

MSTR

NVDA

PLUG

TSLA

벤징가는 지난주 많은 투자자들이 선호하는 주식들의 전망을 조사한 결과를 바탕으로, 주요 뉴스를 요약했다.
S&amp;P 500과 다우 지수가 6주 연속 상승세를 끊고 하락했다. S&amp;P 500은 거의 1% 하락했고, 다우는 2.7% 하락했다. 반면, 나스닥은 7주 연속 상승하며 0.2% 상승하여 사상 최고가를 기록했다. 이는 대형 기술주들의 강력한 실적에 의해 주도되었다.

벤징가 불스 앤 베어스: 엔비디아, 테슬라, 마이크로스트레티지, 플러그 파워 및 도지코인

Biotech

Health Care

Technicals

Signals

General

노보 노디스크 A/S(NYSE:NVO)의 차트에서 기술적 적신호가 발생했다 — 데스 크로스(Death Cross)이다.

노보 노디스크의 데스 크로스: 오젬픽과 위고비 제조사의 전환이 다가오고 있을까?

Global

Economics

Markets

BABA

연방준비제도(연준)가 선호하는 인플레이션 지표인 개인소비지출(PCE) 지수는 8월 이코노미스트들이 예상한 전년 대비 2.2%보다 낮은 성장률을 기록했다. 이 데이터는 4년여 만에 처음으로 연준이 9월 18일 발표한 0.5% 금리 인하 이후에 나온 것이다.

이번 주 시장 동향: S&amp;P 500이 사상 최고치 기록, 브레이너드는 중국산 EV 금지를 지지 등

Novo Nordisk AS

Novo Resources Corp Warrants (27/08/2023)

Novo Integrated Sciences, Inc. - Common Stock

Novo Integrated Sciences Inc

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.00</td>
<td>$44.7K</td>
<td>552</td>
<td>2.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$19.00</td>
<td>$57.0K</td>
<td>804</td>
<td>1.7K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$40.6K</td>
<td>292</td>
<td>866</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$210.00</td>
<td>$32.3K</td>
<td>1.6K</td>
<td>719</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$120.00</td>
<td>$142.8K</td>
<td>2.9K</td>
<td>504</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$800.00</td>
<td>$26.5K</td>
<td>379</td>
<td>274</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$232.6K</td>
<td>1.5K</td>
<td>235</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$55.0K</td>
<td>368</td>
<td>155</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$285.00</td>
<td>$34.5K</td>
<td>428</td>
<td>155</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$365.00</td>
<td>$53.5K</td>
<td>215</td>
<td>108</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding ALLK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>), we observe a call option sweep with bullish sentiment. It expires in 45 day(s) on December 20, 2024. Parties traded 819 contract(s) at a $1.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $44.7K, with a price of $55.0 per contract. There were 552 open contracts at this strike prior to today, and today 2319 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 300 contract(s) at a $19.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $57.0K, with a price of $190.0 per contract. There were 804 open contracts at this strike prior to today, and today 1754 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 58 contract(s) at a $45.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $40.6K, with a price of $700.0 per contract. There were 292 open contracts at this strike prior to today, and today 866 contract(s) were bought and sold. 
• Regarding ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we observe a call option sweep with bearish sentiment. It expires in 73 day(s) on January 17, 2025. Parties traded 719 contract(s) at a $210.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $32.3K, with a price of $45.0 per contract. There were 1601 open contracts at this strike prior to today, and today 719 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 340 contract(s) at a $120.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $142.8K, with a price of $420.0 per contract. There were 2969 open contracts at this strike prior to today, and today 504 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bullish sentiment. It expires in 10 day(s) on November 15, 2024. Parties traded 15 contract(s) at a $800.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $1773.0 per contract. There were 379 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 227 contract(s) at a $50.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $232.6K, with a price of $1025.0 per contract. There were 1525 open contracts at this strike prior to today, and today 235 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 163 day(s) on April 17, 2025. Parties traded 77 contract(s) at a $65.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.0K, with a price of $715.0 per contract. There were 368 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 10 day(s) on November 15, 2024. This event was a transfer of 75 contract(s) at a $285.00 strike. The total cost received by the writing party (or parties) was $34.5K, with a price of $460.0 per contract. There were 428 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 104 contract(s) at a $365.00 strike. This particular call needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $515.0 per contract. There were 215 open contracts at this strike prior to today, and today 108 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALLK

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

10 Health Care Stocks Whale Activity In Today's Session

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 10 years by 6.32% on an annualized basis producing an average annual return of 17.2%. Currently, Novo Nordisk has a market capitalization of $482.39 billion. 
Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $5,007.62 today based on a price of $110.14 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730820641_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today

Novo Nordisk AS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=NVO" target="_blank" rel="noreferrer noopener"> after market hours</a>. 
The stock is up 8.55% over the last year and 7.45% year-to-date.
Let&#8217;s look at what the charts indicate for Novo Nordisk stock and how the stock maps against Wall Street estimates.
<h2 class="wp-block-heading">Novo Nordisk Stock Chart Bearish Ahead Of Q3 Earnings</h2>
Novo Nordisk&#8217;s stock is showing strong bearish momentum, as its price of $108.76 sits below its five- 20- and 50-day exponential moving averages. This downward trend is accompanied by persistent selling pressure, suggesting potential for continued bearish movement.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="625" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05081610/Screenshot-2024-11-05-at-6.30.26-PM.png" alt="" class="wp-image-630249" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05081610/Screenshot-2024-11-05-at-6.30.26-PM.png 625w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05081610/Screenshot-2024-11-05-at-6.30.26-PM-300x218.png 300w" sizes="(max-width: 625px) 100vw, 625px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
With an eight-day simple moving average (SMA) of $111.67, a 20-day SMA of $115.16 and a 50-day SMA of $123.13 — all above the current price — technical indicators point to a bearish signal for NVO stock.
Additionally, the 200-day SMA at $128.29 further underscores the bearish outlook. 
The Moving Average Convergence Divergence (MACD) indicator at a negative 3.44 signals downside momentum, while a Relative Strength Index (RSI) of 25.06 indicates oversold conditions, hinting that NVO stock may face further declines without substantial support or a shift in buying interest.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/41685634/popular-weight-loss-drug-wegovy-shows-encouraging-results-in-liver-fibrosis-trial">Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial</a>
<h2 class="wp-block-heading">New Partnership For Longer-Acting GLP-1 Drugs</h2>
In a significant move to broaden its portfolio, Novo Nordisk has entered into <a href="https://www.benzinga.com/general/biotech/24/11/41723496/wegovy-manufacturer-inks-multi-million-deal-for-monthly-obesity-drug">a $285 million agreement</a> with Denmark-based Ascendis Pharma AS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>). This partnership grants Novo exclusive worldwide rights to Ascendis' TransCon technology, aiming to develop once-monthly GLP-1 receptor agonists for Type 2 diabetes and obesity — a step up from its weekly GLP-1 drugs.
The alliance also covers cardiovascular diseases, with Novo retaining the option to expand future metabolic treatments into additional therapeutic areas. Ascendis will lead early-stage development, while Novo handles the regulatory, manufacturing, and commercial phases.
The lead program in the partnership is a once-monthly GLP-1 drug, a potential game-changer for patients with metabolic disorders. Novo's recent clinical studies underscore the broader health impact of its GLP-1 treatments, showing reduced hospital admissions for heart disease in overweight patients, boosting investor confidence in the potential cardiovascular applications of the new drug.
<h2 class="wp-block-heading">Novo Nordisk Analysts See 46% Upside</h2>
<a href="https://www.benzinga.com/quote/NVO/analyst-ratings" target="_blank" rel="noreferrer noopener">The consensus analyst rating</a> on Novo Nordisk stock stands at a Buy with a price target of $123.86. The latest analyst ratings for Novo Nordisk stock from BMO Capital and Cantor Fitzgerald give an average price target of $158.67, suggesting 45.78% upside potential.
As Novo Nordisk readies to share its third-quarter performance, the dual narratives of bearish technicals and bullish analyst ratings, combined with a groundbreaking new partnership, make the upcoming earnings call a highly anticipated event.
Price Action: Novo Nordisk stock closed the trading day Monday at $109.72, down 1.98%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th">As Race To Best &#8216;Miracle&#8217; Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%</a></li>
</ul>
Image: Shutterstock

Previews

ASND

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?

On Monday, Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) granted Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) an <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41709477/ascendis-pharma-and-novo-nordisk-sign-collaboration-for-development-and-commercialization-of-trans" rel="noreferrer noopener">exclusive worldwide license</a>.
The pact will focus on the TransCon technology platform to develop, manufacture, and commercialize Novo Nordisk proprietary products for metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license for cardiovascular diseases.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40882593/ascendis-pharmas-rare-dwarfism-candidate-shows-promise-in-trial-fda-submission-expected-next-year" rel="noreferrer noopener">Ascendis Pharma&#8217;s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year</a>
The agreement includes provisions requiring certain TransCon technology-based products to be identified and advanced in metabolic diseases to maintain exclusivity in the field and additional provisions for cardiovascular diseases.
Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas.
The lead program in the collaboration is a once-monthly GLP-1 receptor agonist product candidate that will initially target obesity and type 2 diabetes.
Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program.
In addition, Ascendis will be eligible to receive sales-based milestone payments and tiered royalties on global net sales.
For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.
Ascendis will conduct early development of TransCon product candidates in collaboration.
Novo Nordisk will be responsible for these early development costs, clinical development, regulatory, commercial manufacturing, and commercialization.
&#8220;The agreement with Novo Nordisk reflects our Vision 2030 to create value in additional large therapeutic areas outside endocrinology rare disease through collaborations with established global leaders,&#8221; said Jan Mikkelsen, Ascendis Pharma&#8217;s President and CEO.
&#8220;We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases,&#8221; said Brian Vandahl, Senior Vice President of Global Research Technologies at Novo Nordisk.
The transaction is expected to close before the end of 2024.
Price Action: At the last check on Monday, ASND stock was up 1.91% at $127.67, and NVO stock was down 1.61% at $110.14.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41720697/totalenergies-bolsters-lng-presence-in-china-with-15-year-supply-deal-details" target="_blank" rel="noreferrer noopener">TotalEnergies Bolsters LNG Presence In China With 15-Year Supply Deal: Details</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Large Cap

Contracts

Movers

Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug

Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares are moving higher Monday ahead of earnings after the bell. Here&#8217;s what you need to know <a href="https://www.benzinga.com/calendars/earnings">before the report</a>. 
What To Know: Hims &amp; Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Hims &amp; Hers Health has exceeded analyst estimates on the top and bottom lines in three consecutive quarters heading into Monday&#8217;s print. 
Last quarter, the company easily beat estimates as revenue increased 52% year-over-year and subscribers jumped 43% to 1.9 million. 
Hims &amp; Hers Health guided for third-quarter revenue of $375 million to $380 million and raised guidance for the full year from a range of $1.2 billion to $1.23 billion to a new range of $1.37 billion to $1.4 billion. 
&#8220;An approach to democratizing access to high-quality personalized solutions on our platform at an affordable price continues to resonate with consumers. We are seeing this improve our ability to attract new users to longer-tenured specialties, while also allowing us to more rapidly scale new specialties,&#8221; CFO Yemi Okupe said in the earnings release.
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41715442/trump-media-stock-volatile-on-election-eve-as-polls-betting-markets-predict-tight-white-ho">Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race</a>
Hims &amp; Hers Health shares are up approximately 135% year-to-date heading into the print. The stock really took off in May after the company announced it would&nbsp;begin selling compounded versions&nbsp;of GLP-1 injections.
Hims and Hers Health shares experienced increased volatility last month after the FDA removed Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro, which is used to treat diabetes, and weight-loss drug Zepbound from its shortage list. Mounjaro had been on the regulator's shortage list since late 2022, and Zepbound had been on the list since April.
Novo Nordisk&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes drug Ozempic and weight-loss drug Wegovy were also removed from the <a href="https://www.benzinga.com/news/24/10/41636725/hims-hers-health-stock-is-trading-lower-wednesday-heres-why">FDA&#8217;s shortage list</a> last week. 
Hims &amp; Hers Health sells cheaper versions of Eli Lilly and Novo Nordisk&#8217;s drugs, known as compounded drugs. Investors and analysts will be looking for updates in the third-quarter report on how the company expects recent FDA shortage changes to impact the company&#8217;s sales moving forward. 
HIMS Price Action: <a href="http://benzinga.com/quote/hims" target="_blank" rel="noreferrer noopener">Hims &amp; Hers Health shares</a> were up 3.93% at $21.16 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

Earnings

What's Going On With Hims & Hers Health Stock Monday?

Ascendis has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.
In exchange for the license, Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program.&nbsp;
In addition, Ascendis will be eligible to receive sales-based milestone payments and tiered royalties on global net sales. For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.
The closing of this transaction is subject to receipt of applicable regulatory approvals and the parties are seeking to close before the end of 2024.
 &nbsp;

Ascendis Pharma, Novo Nordisk Partner For Development, Commercialization Of TransCon Technology-Based Products In Metabolic, Cardiovascular Diseases; Ascendis To Be Eligible To Receive Payments Of Up To $285M For Lead Program

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide and cagrilintide and aims to reduce weight by 25% without added side effects.
What Happened: The Danish pharmaceutical giant is contending with rivals like Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), also crafting next-gen weight-loss medications. Eli Lilly&#8217;s Zepbound, or Mounjaro, has demonstrated superior weight loss results compared to Novo&#8217;s Wegovy. Novo&#8217;s CagriSema targets a secondary gut hormone, amylin, potentially offering a more potent solution.
The development of the new drug, as <a href="https://www.bloomberg.com/news/features/2024-11-04/ozempic-maker-novo-nordisk-s-new-obesity-drug-targets-biggest-weight-loss-yet">reported</a> by Bloomberg on Monday, seeks to sustain Novo&#8217;s leadership in the fiercely competitive obesity treatment sector.
CagriSema might resolve the prevalent issue of weight regain post-treatment with obesity drugs. The combination of semaglutide and cagrilintide could also be beneficial for type 2 diabetes management. Novo&#8217;s development chief, Martin Holst Lange, has shown optimism about the drug&#8217;s promise, though he refrained from making any guarantees.
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41685445/fda-panel-rejects-lexicons-zynquista-for-type-1-diabetes?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">FDA Panel Rejects Lexicon&#8217;s Zynquista For Type 1 Diabetes</a>
With Novo&#8217;s earnings report approaching and investor concerns mounting, the results from CagriSema&#8217;s extensive clinical trial, anticipated in December, are pivotal. A successful trial could bolster the company&#8217;s market standing, whereas failure might result in substantial financial challenges, as noted by UBS Group AG analyst Jo Walton.
Why It Matters: The obesity drug market is witnessing a transformative phase, with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296978/novo-nordisk-eli-lilly-could-face-downward-pressure-despite-market-dominance-from-p">16 new obesity drugs</a> expected to emerge by 2029, potentially altering the dominance of current leaders like Novo Nordisk and Eli Lilly. These upcoming treatments aim to exceed existing efficacy levels while offering more convenient dosing options, such as oral and monthly injections. This shift, driven by innovation and competition, could reshape the market landscape despite Novo and Lilly&#8217;s current stronghold.
Furthermore, Novo Nordisk is under increasing political scrutiny over the high U.S. prices of its weight-loss drugs, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41025381/exclusive-novo-nordisk-faces-political-heat-over-weight-loss-drug-prices-ahead-of-e">Ozempic and Wegovy</a>, especially as the U.S. presidential election approaches. The significant price disparity between the U.S. and other markets has attracted criticism from lawmakers, placing the company in the political spotlight. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41693101/mercks-gardasil-shot-challenges-to-continue-analysts-optimistic-for-newly-approved-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Merck&#8217;s Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare&nbsp;Lung Disease</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo via Shutterstock

As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3).
Once-weekly, subcutaneous semaglutide 2.4 mg is marketed under the brand name Wegovy.
Part 1 of the ESSENCE trial <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=171971" rel="noreferrer noopener">evaluated</a> the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomized people at 72 weeks.
The trial achieved its primary endpoints by demonstrating a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis and resolution of steatohepatitis with no worsening of liver fibrosis with semaglutide 2.4 mg compared to placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41527988/ozempic-can-potentially-cut-risk-of-alzheimers-compared-to-other-diabetic-medicines-study-shows" rel="noreferrer noopener">Ozempic Can Potentially Cut Risk Of Alzheimer&#8217;s Compared To Other Diabetic Medicines, Study Shows</a>
At week 72, 37.0% of people treated with semaglutide 2.4 mg improved liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo.&nbsp;
62.9% of people treated with semaglutide 2.4 mg achieved resolution of steatohepatitis&nbsp;with no worsening of liver fibrosis compared to 34.1% on placebo.
In the trial, semaglutide 2.4 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 2.4 mg trials.
Novo Nordisk expects to file for regulatory approvals in the U.S. and EU in the first half of 2025.
The detailed results from ESSENCE will be presented at a scientific conference in 2024.
Part 2 of the ESSENCE trial will continue with the expected readout in 2029.
The update comes as the FDA revised its shortage list to&nbsp;<a target="_blank" href="https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Injection&amp;st=c&amp;tab=tabs-1" rel="noreferrer noopener">note</a> that the .25 mg starter dose of semaglutide-based obesity med Wegovy is now available in the U.S.
Less than a month ago, the FDA removed Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide <a target="_blank" href="https://www.benzinga.com/news/24/10/41436151/eli-lilly-sues-some-vendors-for-unauthorized-sale-of-fake-weight-loss-drug" rel="noreferrer noopener">from its shortage list</a>.
In October, Novo Nordisk shared data from the SOUL Phase 3 cardiovascular outcomes trial that evaluated subcutaneous once-weekly (injectable) semaglutide 2.4 mg.
The trial achieved its primary objective by demonstrating a statistically significant and superior reduction in MACE of 14% for people treated with oral semaglutide <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41426815/wegovy-maker-novo-nordisks-oral-diabetes-pill-cuts-heart-attacks-stroke-events-by-14" rel="noreferrer noopener">compared to placebo</a>.
Major adverse cardiovascular events (MACE) are defined as cardiac arrest, stroke, heart failure, or cardiovascular death.
Price Action: NVO stock is up 0.88% at $112.93 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41684029/cardinal-health-raises-2025-profit-outlook-again-helped-by-strong-drug-distribution-business" target="_blank" rel="noreferrer noopener">Cardinal Health Raises 2025 Profit Outlook Again, Helped By Strong Drug Distribution Business</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial

Novo Nordisk's Semaglutide 2.4 mg Achieves Primary Endpoints In Essence Trial, Showing Significant Improvement In Liver Fibrosis And MASH Resolution At Week 72 With Positive Safety Profile; Regulatory Filings Planned For U.S. And EU In 1H 2025, With Detailed Results To Be Presented This Year And Part 2 Readout Expected In 2029

On Thursday,&nbsp;Regeneron Pharmaceuticals&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)&nbsp;reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $11.69</a>.
The company reported sales of $3.72 billion, up 11%, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41647880/regeneron-reports-third-quarter-2024-financial-and-operating-results" rel="noreferrer noopener">consensus of $3.67 billion</a>.
&#8220;Regeneron&nbsp;had a strong third quarter marked by 11% revenue growth. We continued to deepen the impact of our commercialized medicines this quarter, with ongoing leadership for our retinal franchise, expanded global reach of Libtayo, and notable growth from Dupixent,&#8221; said&nbsp;Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of&nbsp;Regeneron.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41208078/regeneron-chief-flags-health-risks-with-popular-weight-loss-medications-like-ozempic-says-company" rel="noreferrer noopener">Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs</a>
&#8220;Our strong third quarter financial performance was highlighted by double-digit revenue growth and continued investment in our growing pipeline,&#8221; said Christopher Fenimore, Senior Vice President, Finance and Chief Financial Officer of Regeneron.
Third quarter 2024 U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;increased 3% versus third quarter 2023 to $1.54&nbsp;billion, including $392 million from Eylea HD.
A lower net selling price adversely impacted the net product sales of EYLEA in the third quarter of 2024.
Libtayo&nbsp;global net sales increased by 25% to $289 million.
Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) collaboration revenue increased from $1.06 billion to $1.26 billion.
The company said its obesity clinical program is now enrolling.
In its earnings <a target="_blank" href="https://investor.regeneron.com/static-files/4ac68b22-7abe-4d1f-a15a-2a9b739cc935" rel="noreferrer noopener">presentation</a>, Regeneron said Phase 2 study to investigate if addition of trevogrumab (anti-myostatin) to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide with and without garetosmab (antiactivin A) improves the quality of weight loss and/or improves maintenance of weight loss post semaglutide discontinuation.
Safety and tolerability data for high-dose trevogrumab in healthy volunteers showed no new safety signals.
The company is on track to complete enrollment by year-end 2024; results for both primary endpoints are expected in 2H25.
Price Action: REGN stock is down 10.7% at $824.28 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41656437/cignas-q3-profit-beats-street-on-strong-demand-for-pharmacy-benefit-managements-specialty-drugs-new" target="_blank" rel="noreferrer noopener">Cigna&#8217;s Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management&#8217;s Specialty Drugs, New Clients</a></li>
</ul>

REGN

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares fell Wednesday following an FDA update listing Novo Nordisk&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here&#8217;s <a href="https://www.benzinga.com/news/24/10/41506422/ozempic-and-wegovy-maker-novo-nordisk-asks-fda-to-halt-production-of-compounded-fat-loss-drugs-due-t">what you need to know.</a>
What Happened: <a href="https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/">A report from the FDA </a>on Wednesday shows that all doses of Novo Nordisk's Ozempic and Wegovy, both GLP-1 receptor agonists, are now available. The change comes after a prolonged shortage of these drugs, which drove demand for compounded versions.
Semaglutide, the active ingredient in both drugs, has been on the FDA's shortage list for over two years. During that time, compounding pharmacies — like those serving Hims &amp; Hers — were legally allowed to create less expensive, compounded versions. 
Hims &amp; Hers stock had previously benefited from the demand for compounded GLP-1 injections and experienced a boost when the company entered this market.
The FDA's announcement suggests Novo Nordisk may soon meet demand, potentially removing Ozempic and Wegovy from the shortage list. Without a shortage, compounding pharmacies may lose the regulatory allowance to produce these alternatives. This may directly impact revenue for companies like Hims &amp; Hers that rely on sales of compounded versions.
HIMS Price Action: Hims &amp; Hers Health shares were down 14.31% at $19.04 at market close Wednesday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="527" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30154523/HIMS-1024x527.png" alt="" class="wp-image-622669" style="width:494px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30154523/HIMS-1024x527.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30154523/HIMS-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30154523/HIMS-768x395.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30154523/HIMS.png 1168w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41635030/future-proofing-cannabis-facilities-grow-americas-approach-to-shifting-regulations">Future-Proofing Cannabis Facilities: Grow America&#8217;s Approach To Shifting Regulations</a></li>
</ul>
Image Via Shutterstock.

Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/10/2024-10-30_07h53_04.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Strong ADP Data</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-tech-earnings-nvidia-software-amd-mc-10302024">click here </a>for an enlarged chart of Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock. The chart of AMD stock is being used to illustrate the point.</li>
<li>The chart shows the momo crowd buying AMD stock yesterday ahead of the earnings release.</li>
<li>The chart shows when earnings were released.</li>
<li>The chart shows the drop in AMD stock after earnings.</li>
<li>The chart shows the proprietary Arora Report VUD indicator changed to orange when earnings were released and continues to be orange today in the premarket.&nbsp; This indicates a net supply of AMD stock.</li>
<li>AMD reported earnings inline with the consensus and provided decent guidance.&nbsp; Why did the stock fall?&nbsp; The reason is that the whisper numbers for AI GPU guidance were approaching $6B.&nbsp; AMD guided above $5B for 2024 – this was inline with consensus.&nbsp; As we have been sharing with you, stocks move based on the difference between reported numbers and whisper numbers.</li>
<li>The reason that AMD was not able to meet the whisper numbers is that even though AMD chips for AI are excellent, AMD does not have the software and the whole system like NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).&nbsp; This limits AMD's market even though AMD is offering cheaper price points compared to Nvidia.&nbsp; AMD has recently bought a systems company in an attempt to catch up to NVDA.&nbsp; However, in The Arora Report analysis, it will take a long time for AMD to catch up with NVDA.&nbsp; Nvidia's CUDA is a parallel computing platform and programming model.&nbsp; Thousands of developers have been using CUDA to harness the power of AI for years.</li>
<li>Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) reported earnings yesterday after the close.&nbsp; Alphabet earnings show data center growth.&nbsp; Data center growth means AI growth.&nbsp; However, in The Arora Report analysis, there is risk in GOOG stock because Google has over 90% of the search market.&nbsp; It is hard to see Google gaining share from here.&nbsp; Even a drop of a few percentage points will substantially hit earnings.</li>
<li>Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) earnings are ahead after the close.&nbsp; In The Arora Report analysis, stocks will move based not only on the earnings but how well the companies are able to monetize AI.</li>
<li>The Arora Report shared early on that AI was real and a fortune was to be made from AI.&nbsp; We have also been sharing with you that it is important to develop deep knowledge because at times it will be treacherous.&nbsp; We have illustrated the treacherousness of following the momo crowd in AI with the example of Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).&nbsp; When everyone was bullish and SMCI was trading above $120, The Arora Report call was that SMCI was worth only $44 &#8211; $48 at best.&nbsp; SMCI is falling about 33% to about $32 as of this writing in the premarket on the news that its independent auditor resigned.</li>
<li>Just released GDP data shows that the economy is strong even though the numbers are less than the consensus.&nbsp; GDP is a lagging indicator.&nbsp; The Arora Report system focuses on leading indicators.&nbsp; Here are the details of the GDP data:
<ul>
<li>Q3 GDP-Adv came at 2.8% vs. 3.0% consensus.</li>
<li>Q3 Chain Deflator-Adv came at 1.8% vs. 2.3% consensus.</li>
</ul>
</li>
<li>Automatic Data Processing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) data indicates a strong jobs picture.&nbsp; ADP is the largest payroll processor in the country and uses its data to give an advanced glimpse of the jobs picture ahead of the official jobs report that will be released on Friday at 8:30am ET.&nbsp; In The Arora Report analysis, if the official jobs report also shows a strong jobs picture, it will decrease the probability that the Fed will cut interest rates at the next meeting.&nbsp;&nbsp;
<ul>
<li>ADP employment change came at 223K vs. 105K consensus.</li>
</ul>
</li>
<li>ADP data is one more data point that has gone against the reason the Fed gave to cut interest rates by 50 bps in September.&nbsp; As we have been writing, almost all of the data has gone against the Fed's reasoning for cutting rates by 50 bps.&nbsp;&nbsp;</li>
<li>In a major setback, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) missed the earnings consensus.&nbsp; LLY stock has fallen about 10% as of this writing in the premarket.&nbsp; In sympathy, the stock of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) is also falling.&nbsp; LLY and NVO stocks have been riding high on weight loss drugs.&nbsp; As full disclosure, LLY stock is in The Arora Report&#8217;s ZYX Buy Core Model Portfolio, long from $318.45.&nbsp; As of this writing, LLY stock is trading at $807.</li>
<li>Jobless claims, personal income and spending, and &nbsp;Fed&#8217;s favorite inflation gauge PCE will all be released tomorrow at 8:30am ET.</li>
</ul>
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), MSFT, GOOG, and META.
In the early trade, money flows are negative in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), and NVDA.
In the early trade, money flows are negative in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.&nbsp; Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.&nbsp; The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).&nbsp; The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).&nbsp; The most popular ETF for oil is United States Oil ETF (ASCA:USO).
<h3 class="wp-block-heading">Bitcoin</h3>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is range bound.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Tech

AMZN

GOOG

MSFT

SMCI

AMD Earnings Show Power Of Nvidia Software, ADP Data Defies Expectations

<a href="https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/">https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/</a>
All doses of Novo Nordisk&#39;s blockbuster diabetes and obesity treatments are <a href="https://dps.fda.gov/drugshortages/activeingredient/semaglutide-injection">listed as available</a> on the Food and Drug Administration&#39;s drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs.
Semaglutide, the scientific name for Novo&#39;s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times. With all doses now listed as available, the FDA may soon pull it off the list, depending on its conversations with Novo about whether the company can sufficiently meet demand going forward.
Over the past two years, patients seeking treatment have been turning to compounding pharmacies, which make cheaper copies of branded treatments and are legally allowed to do so only when the branded treatments are listed on the FDA&#39;s shortage list.&nbsp;

&nbsp;

DRIO

RHHBY

TERN

VANI

VKTX

Reported Earlier, 'Novo Nordisk's Ozempic and Wegovy, long in shortage, are now listed as available by FDA; It remains unclear how the update could affect patients as well as compounders' - STAT News

Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) short percent of float has fallen 9.09% since its last report. The company recently reported that it has 6.36 million shares sold short, which is 0.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novo Nordisk Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730295913_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novo Nordisk has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Novo Nordisk's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novo Nordisk's peer group average for short interest as a percentage of float is 4.52%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

How Is The Market Feeling About Novo Nordisk?

TLSA

Tiziana Life Sciences Reports Preclinical Results For Combination Of Nasal Anti-CD3 Antibody And Semaglutide (Ozempic) In Reducing Inflammation And Improving Liver Health In Diet-Induced Obesity Models

Novo Nordisk shares are trading lower in possible sympathy with Lilly, which fell after worse-than-expected Q3 financial results.

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) revealed 20 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 65% showed bearish tendencies. Out of all the trades we spotted, 13 were puts, with a value of $1,082,396, and 7 were calls, valued at $325,455.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $145.0 for Novo Nordisk over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 1369.56 with a total volume of 9,676.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Novo Nordisk's big money trades within a strike price range of $100.0 to $145.0 over the last 30 days.
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730221239_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$6.2</td>
<td>$6.15</td>
<td>$6.2</td>
<td>$110.00</td>
<td>$302.5K</td>
<td>3.6K</td>
<td>489</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$6.15</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$110.00</td>
<td>$233.1K</td>
<td>3.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.45</td>
<td>$3.4</td>
<td>$3.45</td>
<td>$116.00</td>
<td>$103.5K</td>
<td>99</td>
<td>300</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$32.5</td>
<td>$32.35</td>
<td>$32.5</td>
<td>$145.00</td>
<td>$91.0K</td>
<td>334</td>
<td>50</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$1.48</td>
<td>$1.23</td>
<td>$1.34</td>
<td>$111.00</td>
<td>$75.3K</td>
<td>507</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,941,769, the price of NVO is down by -0.66%, reaching $111.62.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 8 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Novo Nordisk</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $158.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Novo Nordisk, targeting a price of $156. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on NVO Options

<a href="https://www.fda.gov/media/183181/download" title="https://www.fda.gov/media/183181/download">https://www.fda.gov/media/183181/download</a>

FDA Inspection Flags Multiple Compliance Issues At Novo Nordisk's Denmark Site, Including Insufficient Sample Volume, Poor Microbial Control, Undocumented Processes, Incomplete Records, And Lapses In Quality Oversight

Tesla and SpaceX CEO Elon Musk has hinted at the possibility of his brain-machine interface company, Neuralink, developing an implant for early-stage Alzheimer&#8217;s disease.
What Happened: Sharing a clip from his <a href="https://www.benzinga.com/news/24/10/41591053/elon-musk-says-neuralink-brain-implants-could-cost-as-little-as-an-apple-watch-we-do-have-a-game-pla">appearance at the 2024 Congress</a> of&nbsp;Neurological Surgeons last month, Musk took to X, formerly Twitter, and suggested that Neuralink should focus on creating an implant to alleviate back and neck pain.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I am increasingly convinced that <a href="https://twitter.com/neuralink?ref_src=twsrc%5Etfw">@Neuralink</a> should prioritize making an implant that can eliminate back &amp; neck pain. Would greatly improve people's happiness while awake, as well as enhance quality of sleep. <a href="https://t.co/kabge5XRuH">pic.twitter.com/kabge5XRuH</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1851046159743402482?ref_src=twsrc%5Etfw">October 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/general/biotech/24/10/41529605/just-after-pfizers-rsv-vaccine-approval-for-younger-adults-gsk-layouts-encouraging-preliminary-da?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Just After Pfizer&#8217;s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population</a>
When a user questioned Neuralink&#8217;s potential role in Alzheimer&#8217;s treatment, the tech mogul said,&nbsp;&#8220;Early stage, yes, but only&nbsp;limited help is possible for&nbsp;late-stage Alzheimer's, as &nbsp;there is too much neuronal&nbsp;loss.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Early stage, yes, but only limited help is possible for late stage Alzheimer's, as there there is too much neuronal loss
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1851048183700603258?ref_src=twsrc%5Etfw">October 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Previously also, Musk had stated that the <a href="https://www.benzinga.com/news/22/04/26778138/elon-musk-says-his-neuralink-chip-can-bridge-broken-links-between-brain-body">Neuralink chip could help treat</a> conditions like paralysis, stroke, and brain injury, as well as morbid obesity.
&#8220;Current generation Neuralinks can help to some degree, but an advanced case of Alzheimers often involves macro degeneration of the brain,&#8221; he stated in 2022.
&#8220;However, Neuralinks should theoretically be able restore almost any functionality lost due &#x2A;localized&#x2A; brain damage from stroke or injury.&#8221;
Alzheimer&#8217;s is a progressive brain disorder that impairs memory and cognitive function. Nearly seven million Americans aged 65 and older are living with the condition.
Meanwhile, healthcare companies, such as&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), have also been exploring treatments for Alzheimer&#8217;s.
Earlier, it was reported that Novo Nordisk&#8217;s semaglutide may reduce the risk of Alzheimer&#8217;s in individuals with type 2 diabetes, while Eli Lilly&#8217;s Kisunla (donanemab) has been approved for adults with <a href="https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke">early symptomatic Alzheimer&#8217;s disease</a> in Japan.&#8217;
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41570381/dutch-health-tech-firm-philips-q3-earnings-miss-expectations-lowers-annual-forecasts-on-weak-demand?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dutch Health Tech Firm Philips&#8217; Q3 Earnings Miss Expectations, Lowers Annual Forecasts On Weak Demand In China</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Neuralink's Promise For Alzheimer's Has A Crucial Time Window — Elon Musk Explains Why

<a href="https://www.ema.europa.eu/en/documents/shortage/norditropin-somatropin-supply-shortage_en.pdf" title="https://www.ema.europa.eu/en/documents/shortage/norditropin-somatropin-supply-shortage_en.pdf">https://www.ema.europa.eu/en/documents/shortage/norditropin-somatropin-supply-shortage_en.pdf</a>

UK's EMA Says Novo Nordisk Decided Norditropin Nordiflex Will Be Discontinued Entirely; Discontinuation Of Norditropin Nordiflex To Come Into Effect From 2024 End, Timelines May Vary From Country To Country

AstraZeneca (AZN) said Monday at the ObesityWeek conference in San Antonio, Texas that its experimental obesity pill was well-tolerated by patients...

AstraZeneca says experimental obesity pill 'competitive,' Bloomberg reports

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

New study reveals another benefit in using Novo Nordisk's Wegovy in obesity

Viking stock drops 13% after jumping 9% on obesity drug data

How does Viking's weight loss med compare to ones from Novo, Eli Lilly?

4-Factor Dividend Growth Portfolio: FY3 Rebalance And 21.57% Long-Term CAGR

Hims & Hers to launch a generic for Novo's older GLP-1

Novo Nordisk (NVO) has released an update. Novo Nordisk has successfully concluded a share repurchase program initiated on August 7, 2024, buying b...

Novo Nordisk Completes DKK 2.4 Billion Share Buyback

Novo Nordisk Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

ABEV

ABUS

ADRNY

ASML

ATHM

AUDC

AZNCF

BMWYY

CDXC

CELH

CLBT

CNDT

CTAS

EHTH

ENOV

EPIX

FANG

FOLD

HENKY

INFY

IONS

LNTH

LRCX

MCFT

MDGL

MKTX

MOGO

MPWR

MSCI

NEON

NONOF

ODFL

OESX

PAYX

PERI

PFGC

PRGO

RPRX

SCHD

SNDR

STWD

TCPC

TEVA

TRMB

URGN

VONOY

VRNOF

Screenshot 2024-09-10 at 4.29.40 PM

BRTX

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors

Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033

RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Management

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Opinion

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

Comments

Novo Nordisk

Novo Nordisk (NVO) 옵션

Novo Nordisk (NYSE:NVO) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌